Filing Details
- Accession Number:
- 0001127602-12-032319
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-11-29 19:55:42
- Reporting Period:
- 2012-11-27
- Filing Date:
- 2012-11-29
- Accepted Time:
- 2012-11-29 19:55:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
850693 | Allergan Inc | AGN | Pharmaceutical Preparations (2834) | 951622442 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1532023 | S Julian Gangolli | 2525 Dupont Drive Irvine CA 92612 | Cvp & Pres, North America | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-11-27 | 4,622 | $58.55 | 20,403 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2012-11-27 | 30,000 | $40.16 | 50,403 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-11-27 | 34,622 | $92.25 | 15,781 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2012-11-28 | 55,378 | $58.55 | 71,159 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-11-28 | 55,378 | $91.66 | 15,781 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-11-27 | 4,622 | $0.00 | 4,622 | $58.55 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-11-27 | 30,000 | $0.00 | 30,000 | $40.16 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-11-28 | 55,378 | $0.00 | 55,378 | $58.55 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
55,378 | 2017-02-02 | No | 4 | M | Direct | |
15,000 | 2019-02-20 | No | 4 | M | Direct | |
0 | 2017-02-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 220 | Indirect | By ESOP Trust |
Common Stock | 12,172 | Indirect | By The Gangolli Family Trust |
Common Stock | 264 | Indirect | By Wife's 401(k) plan |
Footnotes
- The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $92.25 to $92.31, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $91.34 to $91.88, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- Includes shares acquired under the Allergan, Inc. Dividend Reinvestment Plan.
- Shares allocated to the reporting person's ESOP account as of reporting date.
- Shares held by The Gangolli Family Trust established June 1, 2011, of which the reporting person and his spouse are each trustees.
- The option became exercisable in four equal annual installments beginning February 2, 2008.
- The option became exercisable in four equal annual installments beginning February 20, 2010. The remaining outstanding options for this award are reported in this filing.